Caring Brands (CABR) investor relations material

Company overview and business model

• Operates as a wellness consumer products company offering OTC and cosmetic products for hair loss, eczema, psoriasis, vitiligo, suncare, and women's wellness, with a focus on clinically validated, patent-protected formulations and commercial stability.

• Incorporated in Nevada in April 2024 following a separation from Safety Shot, Inc.; Caring Brands Florida is its main operating subsidiary.

• Products are sold online, with early-stage commercialization in India and the U.S.; expansion into additional e-commerce and retail channels is planned.

• Holds exclusive licenses for key products in multiple territories, including India, Japan, and 31 other countries, and is pursuing further licensing and acquisition opportunities.

Financial performance and metrics

• Reported nominal revenues of $4,215 in 2025 and $465 in 2024, reflecting early commercialization stage.

• Net loss of $6,278,191 for 2025, compared to a net loss of $1,517,431 for 2024, driven by increased operating expenses, impairment of intellectual property, and investment losses.

• Cash and cash equivalents were $2,189,232 as of December 31, 2025, up from $468,998 at year-end 2024, primarily due to IPO proceeds.

• Operating expenses rose to $5,937,367 in 2025, reflecting higher payroll, professional fees, and full-year amortization of IP licenses.

• Accumulated deficit reached $7,140,982 as of December 31, 2025; management believes cash on hand is sufficient for at least 12 months.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; may receive up to $3.789 million if all warrants are exercised for cash.

• Any warrant exercise proceeds will be used for general corporate purposes and working capital, with management retaining discretion over allocation.

• Recent capital was used to repurchase 6,250,000 shares from insiders and settle related party transactions.